Incretin raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-02-21 and is reviewed periodically as new material appears.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Free base form |
| Molecular mass | Approximately 4813 Da | Calculated from the sequence |
| Amino acid residues | 39 | GIP-derived backbone |
| Receptor targets | GIP and GLP-1 | Dual agonist |
| Circulating half-life | About 5 days | Supports weekly administration |
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
=== Herbivores === Herbivores consume ionone-containing carotenoids and convert those to retinal. Some species, including cattle and horses, have measurable amounts of β-carotene circulating in the blood, and stored in body fat, creating yellow fat cells. Most species have white fat and no β-carotene in circulation.
== Biography == Taylor was born on March 12, 2001, in Gilbert, Arizona, to a Black father and a white mother. She grew up with what she's described as a "messy home life", as her parents divorced when she was 7. This drove her towards the Mormon church, as she was interested in its focus on family. She began sneaking away from home to attend church services, and eventually became baptized as a Mormon. She had planned to attend the University of California, Irvine, which she had been accepted to, but ultimately decided to instead move to Utah, where she lived on the campus of Brigham Young University. She worked as a nanny while training to be a dental assistant. She began using a Mormon dating app. Within a week, she met the man she would go on to marry. After an on-and-off year of dating, she got pregnant, and they got married one month later. Thirteen months after the birth of her first child, she gave birth to a second child. Ultimately, however, she divorced her husband and left her relationship, which she has subsequently described as a "toxic" relationship. She has identified as a survivor of domestic abuse in connection with it. She has discussed her subsequent struggles as a single mother, including skipping eating in order to feed her kids and being unable to work as she couldn't afford daycare. She eventually started posting to TikTok, and received a few thousand followers. Soon, however, Taylor Frankie Paul invited her to join a group called MomTok. This eventually resulted in her casting in The Secret Lives of Mormon Wives.
According to the 1996 edition of Vogel's Textbook, yields close to 100% are called quantitative, yields above 90% are called excellent, yields above 80% are very good, yields above 70% are good, yields above 50% are fair, and yields below 40% are called poor. In their 2002 publication, Petrucci, Harwood, and Herring wrote that Vogel's Textbook names were arbitrary, and not universally accepted, and depending on the nature of the reaction in question, these expectations may be unrealistically high. Yields may appear to be 100% or above when products are impure, as the measured weight of the product will include the weight of any impurities. In their 2016 laboratory manual, Experimental Organic Chemistry, the authors described the "reaction yield" or "absolute yield" of a chemical reaction as the "amount of pure and dry product yielded in a reaction". They wrote that knowing the stoichiometry of a chemical reaction—the numbers and types of atoms in the reactants and products, in a balanced equation "make it possible to compare different elements through stoichiometric factors." Ratios obtained by these quantitative relationships are useful in data analysis.
== Contraindications == In the US the only contraindication for tetracosactide for diagnostic use is hypersensitivity to ACTH but in the UK, regulators placed contraindications for hypersensitivity to ACTH and additionally, for people with allergic disorders including asthma, acute psychosis, infectious diseases, peptic ulcer, refractory heart failure, Cushing's syndrome, treatment of primary adrenocortical insufficiency and adrenocongenital syndrome. The same contraindications that were applied in the UK for diagnostic use of tetracosactide, apply for therapeutic use of both tetracosactide and corticotropin in the US and UK. In addition, the US label for corticotropin for therapeutic uses includes contraindications for people who have recently had surgery, and people with scleroderma, osteoporosis, uncontrolled hypertension, or sensitivity to proteins of porcine origin; in addition the infection diseases systemic fungal infection, ocular herpes simplex, and infants who have congenital infections are specified. The label also notes that people taking corticotropin for immunosuppression should not be given live vaccines.
Sources: en.wikipedia.org
=== Arrival in Washington === Nixon had been elected in 1968 on the promise of achieving "peace with honor" and ending the Vietnam War. By promising to continue the peace talks which Johnson began in May 1968 in Paris, Nixon admitted that he had ruled out "a military victory" in Vietnam. Nixon wanted a diplomatic settlement similar to the armistice of Panmunjom that ended the Korean War and frequently stated in private he had no intention of being "the first president of the United States to lose a war". To force the North Vietnamese to sign an armistice, Nixon favored a two-pronged approach of the "madman theory" of seeking to act rashly to intimidate the North Vietnamese while at the same time trying using the strategy of "linkage" to improve relations with the Soviet Union and China in order to persuade both these nations to stop sending arms to North Vietnam. In office, Nixon implemented a policy of Vietnamization that aimed to gradually withdraw U.S. troops while expanding the combat role of the South Vietnamese Army so that it would be capable of independently defending its government against the National Front for the Liberation of South Vietnam, a Communist guerrilla organization, and the North Vietnamese army (Vietnam People's Army or PAVN). Kissinger was opposed to Vietnamization.
Necrotizing fasciitis is ideally a clinical diagnosis based on symptoms. Due to the need for rapid surgical treatment, the time delay in performing imaging is a major concern. Hence, imaging may not be needed if signs of a necrotizing infection are clear. However, due to the vague symptoms associated with the earlier stages of this disease, imaging is often useful in clarifying or confirming the diagnosis. Both CT and MRI scans are used to diagnose NF, but neither is sensitive enough to rule out necrotizing changes completely.
Ho's extensive research achievements have garnered news coverage in The Economist, Forbes, Nature, CNN, NPR, as well as The Washington Post. He was also featured in the National Geographic Channel program, Known Universe. Most recently, the Augmented AI platform was featured by FuturizeX, a partnership between the X PRIZE Foundation and UCLA. Recent clinical advances using this AI approach to enhance clinical outcomes were recognized among the finalists for the SLAS Innovation Award, selection among the SLAS Technology 10, and featured at the PM3 panel at InnovFest Unbound. Ho currently serves as the Director of The N.1 Institute for Health (N.1), which was previously known as SINAPSE, as well as Director of the Institute for Digital Medicine (WisDM) at the Yong Loo Lin School of Medicine, National University of Singapore. N.1 and WisDM are clinical stage research institutes that harnesses AI and Digital Medicine for novel clinical trial designs for interventional studies. Over ten first-in-human clinical studies based on N.1 and WisDM-developed technologies are ongoing or nearing clearance for the start of prospective clinical studies. N.1 and WisDM have pioneered the development and subsequent clinical translation of platforms pertaining to N-of-1 medicine, digital therapeutics, COVID-19 therapeutic regimen optimization, pain management, cognitive neuroengineering, and novel drug development, among many others. Ho is an elected member of the US National Academy of Inventors (NAI).
Sources: en.wikipedia.org
== RNA-DNA world == In 2020, coevolution of a RNA-DNA mixture based on diamidophosphate was proposed. The mixture of RNA-DNA sequences, called chimeras, have weak affinity and form weaker duplex structures. This is advantageous in an abiotic scenario and these chimeras have been shown to replicate RNA and DNA – overcoming the "template-product" inhibition problem, where a pure RNA or pure DNA strand is unable to replicate non-enzymatically because it binds too strongly to its partners. This could lead to an abiotic cross-catalytic amplification of RNA and DNA. A continuous chemical reaction network in water and under high-energy radiation can generate precursors for early RNA. In 2022, evolution experiments of self-replicating RNA showed how RNA may have evolved to diverse complex molecules in RNA world conditions. The RNA evolved to a "replicator network comprising five types of RNAs with diverse interactions" such as cooperation for replication of other members (multiple coexisting host and parasite lineages).
However, on April 9, Dana White, the president of UFC announced that this event was postponed to a future date Instead Casey is scheduled to face Mara Romero Borella on May 16, 2020 at UFC on ESPN: Overeem vs. Harris. She won the bout in the first round via submission through an armbar. This win earned her the Performance of the Night award. Casey faced Gillian Robertson on June 20, 2020 at UFC Fight Night: Blaydes vs. Volkov. She lost the fight via a rear-naked choke submission in round three. Casey was expected to face Priscila Cachoeira on October 31, 2020 at UFC Fight Night 181. However the bout was called off the day of the weigh-ins as Cachoeira had issues cutting weight. Casey faced JJ Aldrich on March 13, 2021 at UFC Fight Night 187. She lost the fight via split decision. Casey was expected to face Liana Jojua on August 21, 2021 at UFC on ESPN 29. However, Jojua was forced out of the fight due to visa issues. The matchup was rescheduled at UFC Fight Night 197 on November 13, 2021. At the weigh-ins, Jojua weighed in at 128.5 pounds, two and a half pounds over the flyweight non-title fight limit. The bout proceeded at a catchweight with Jojua fined 30% of her purse, which went to her opponent Casey. Casey won the bout via unanimous decision. Casey was scheduled to face Antonina Shevchenko on April 30, 2022 at UFC on ESPN 35. However, the bout was postponed to July 9, 2022 at UFC on ESPN 39 due Shevchenko injured her knee in training. Casey lost the fight via split decision. Casey was scheduled to face Jasmine Jasudavicius on February 25, 2023, at UFC Fight Night 220.
=== Genetically encoded polymers === Chilkoti is most known for his work on genetically engineered elastin-like polypeptides (ELPs), which exhibit thermally responsive behavior and have been exploited by his group to develop new technologies and materials for protein purification, controlled drug release, and tissue engineering. He has also pioneered the development of high-throughput and scalable methods for the recombinant synthesis of repetitive peptide polymers that are useful for the recombinant synthesis of ELPs and other repetitive polypeptides. He developed a new non-chromatographic method for the purification of proteins. He also pioneered the development of injectable depots of ELPs fused to peptide and protein drugs for sustained—week or longer—release, and ELP nanoparticles loaded with small molecule chemotherapeutics for cancer therapy. His research group also developed a new class of partially ordered polypeptides that undergo a phase transition from a liquid into a highly porous solid network at body temperature.
Although 54.0% of the population lived in urban areas in 2011, this percentage has been declining since 1996. Counties with over 2⁄3 urban population are Hunedoara, Brașov and Constanța, while those with less than a third are Dâmbovița (30.06%) and Giurgiu and Teleorman. Bucharest is the capital and the largest city in Romania, with a population of over 1.7 million in 2021. Its larger urban zone has a population of almost 2.2 million, which are planned to be included into a metropolitan area up to 20 times the area of the city proper. Another 17 cities have a population of over 100,000, with Cluj-Napoca, Iași, Constanța and Timișoara having more than 250,000 inhabitants, and Craiova, Brașov and Galați with over 200,000 inhabitants. Metropolitan areas have been constituted for most of these cities.
Sources: en.wikipedia.org
It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.
A fatty diacid side chain promotes binding to albumin, which delays clearance from circulation. The half-life of roughly five days makes a weekly schedule practical.
No. It is a synthetic peptide whose backbone is based on the natural incretin hormone GIP. Non-natural residues and the lipid side chain were engineered to improve stability and duration of action.
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.